A recent narrative review published in the journal Pharmacia critically evaluates the current evidence regarding three specific complementary nutritional supplements: vitamin D, berberine, and chromium. The study synthesized mechanistic, preclinical, observational, and clinical data from publications between 2010 and March 2026 to provide an integrated comparative evaluation of these compounds. Unlike previous reviews that often examined these supplements in isolation, this research offers a unified framework to understand how they influence insulin resistance through distinct but potentially complementary mechanisms. The findings suggest that while these supplements show promise, their clinical efficacy is highly dependent on individual metabolic phenotypes and baseline nutritional status.

Vitamin D has attracted significant attention due to its involvement in vitamin D receptor-mediated regulation of insulin signaling and pancreatic beta-cell function. Observational studies consistently demonstrate an inverse association between circulating vitamin D levels and markers of insulin resistance, such as HOMA-IR and fasting glucose. In prediabetic animal models, vitamin D3 supplementation has been shown to improve glucose regulation by modulating key signaling pathways like IRS-1 and PPARγ. However, clinical trial data remains heterogeneous, with benefits appearing most evident in individuals who have baseline vitamin D deficiency, obesity, or elevated cardiometabolic risk. The sequestration of vitamin D within adipose tissue in obese individuals may partly explain the reduced bioavailability and the variable responses observed in clinical settings.

Berberine, a plant-derived isoquinoline alkaloid, is perhaps the most extensively investigated nutraceutical in the context of insulin resistance. Its primary mechanism involves the activation of AMP-activated protein kinase (AMPK), a critical regulator of cellular energy metabolism. Through this pathway, berberine enhances peripheral glucose uptake, suppresses hepatic gluconeogenesis, and promotes fatty acid oxidation. Clinical studies have reported favorable effects on fasting glucose, HbA1c, triglycerides, and inflammatory markers in patients with metabolic syndrome and type 2 diabetes. Despite its promising metabolic profile, berberine is limited by low oral bioavailability due to poor intestinal absorption and first-pass hepatic metabolism. Additionally, gastrointestinal adverse effects and potential drug interactions via CYP450 enzymes and P-glycoprotein require careful consideration in clinical practice.

Chromium, an essential trace element, is proposed to enhance insulin receptor activity and support the PI3K/Akt signaling cascade, thereby improving cellular glucose uptake. While some randomized controlled trials have demonstrated modest improvements in glycemic control and insulin sensitivity, the overall evidence is more inconsistent compared to vitamin D and berberine. The variability in clinical outcomes is likely attributable to differences in chromium formulation, dosage, and the baseline chromium status of participants. Chromium picolinate is the most commonly used supplemental form, but the absence of standardized biomarkers for assessing chromium deficiency limits the ability to target supplementation effectively. Current evidence suggests that chromium may benefit selected individuals with impaired glucose metabolism or suspected deficiency, but it does not support universal supplementation for all patients with insulin resistance.

The comparative analysis highlights that the three supplements target different components of insulin resistance pathophysiology. Vitamin D primarily regulates insulin sensitivity through receptor-mediated signaling and inflammatory modulation, while berberine exerts pleiotropic effects through AMPK activation and gut microbiota modulation. Chromium acts predominantly by potentiating insulin receptor activity and downstream signaling. The strength of clinical evidence varies among them, with berberine showing moderate to relatively strong support from multiple randomized trials, vitamin D having a strong biological rationale but heterogeneous intervention data, and chromium presenting the greatest uncertainty. This diversity in mechanisms and evidence strength underscores the complexity of managing insulin resistance and the need for a nuanced, individualized approach to nutritional supplementation.

A major finding from the review is that variability in treatment response cannot be explained solely by the supplements themselves. Instead, it reflects substantial biological and methodological heterogeneity across studies, including differences in obesity status, baseline nutritional deficiencies, intervention protocols, and outcome measures. This suggests that a one-size-fits-all approach to supplementation is unlikely to be effective. The evidence increasingly supports a phenotype-oriented strategy, where supplementation is targeted to patients most likely to benefit, such as those with documented micronutrient deficiencies, obesity, prediabetes, or metabolic dysfunction-associated steatotic liver disease. This perspective aligns with the broader shift toward precision nutrition and personalized metabolic medicine, where clinical decisions are guided by individual metabolic characteristics.

Safety profiles are also a critical consideration when integrating these supplements into clinical practice. Vitamin D is generally well-tolerated, though excessive dosing may increase the risk of hypercalcemia. Berberine is associated with mild gastrointestinal effects and potential drug interactions, necessitating caution in patients on multiple medications. Chromium is considered safe at nutritional doses, but long-term safety data and optimal dosing strategies remain uncertain, particularly in patients with renal impairment or polypharmacy. The review emphasizes that these supplements should be viewed as adjuncts to lifestyle modification and evidence-based therapy, not as stand-alone treatments. Careful patient selection and monitoring are essential to maximize benefits while minimizing potential risks.

The study concludes that future research must focus on adequately powered randomized controlled trials that employ standardized formulations and phenotype-specific patient stratification. Such studies are necessary to clarify the long-term efficacy, safety, and precise role of these supplements in personalized metabolic management. By integrating nutritional supplementation into routine clinical assessment, clinicians can better identify patients who are likely to respond to targeted interventions. This approach may improve therapeutic effectiveness while avoiding unnecessary treatment in individuals unlikely to benefit. Ultimately, the management of insulin resistance requires a comprehensive strategy centered on lifestyle optimization, weight control, and regular physical activity, with complementary nutritional supplementation serving as a supportive element in a broader, patient-centered therapeutic plan.

Subject of Research: Complementary nutritional supplementation in insulin resistance: The role of vitamin D, berberine and chromium

Article Title: Complementary nutritional supplementation in insulin resistance: The role of vitamin D, berberine and chromium

Article References: Todorova, G., Gesheva, T., Boycheva, N., & Mihaylova, A. (2026). Complementary nutritional supplementation in insulin resistance: The role of vitamin D, berberine and chromium. Pharmacia, 73, Article e207685. https://doi.org/10.3897/pharmacia.73.e207685

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e207685

Keywords: Complementary, nutritional, supplementation, insulin, resistance, role, vitamin, berberine, chromium, scientific research